Year: 2014
Type: article
Abstract: The current editorial focuses on a phase 2 study evaluating ramucirumab in patients with metastatic renal cell carcinoma (mRCC) who have received prior sunitinib and/or sorafenib therapy. The potential for further development is discussed in the context of the rapidly changing landscape of therapy for mRCC.
Source: Cancer
DOI: 10.1002/cncr.28636
Authors: Sumanta K. Pal, Robert A. Figlin
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W1506146499